Edition:
United States

Neovasc Inc (NVCN.OQ)

NVCN.OQ on NASDAQ Stock Exchange Capital Market

0.24USD
3:57pm EST
Change (% chg)

$-0.02 (-7.75%)
Prev Close
$0.26
Open
$0.27
Day's High
$0.27
Day's Low
$0.23
Volume
606,223
Avg. Vol
190,495
52-wk High
$2.12
52-wk Low
$0.23

Chart for

About

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment... (more)

Overall

Beta: 3.21
Market Cap(Mil.): $33.49
Shares Outstanding(Mil.): 101.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.68 16.52
EPS (TTM): -- -- --
ROI: -- 9.69 36.19
ROE: -- 14.25 17.38

BRIEF-Neovasc Receives German Nub Status 1 Designation For Neovasc Reducer Procedure

* NEOVASC ANNOUNCES RECEIPT OF GERMAN NUB STATUS 1 DESIGNATION FOR NEOVASC REDUCER™ PROCEDURE FOR TREATMENT OF REFRACTORY ANGINA Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Fred Colen Appointed CEO Of Neovasc Inc

* FRED COLEN APPOINTED CHIEF EXECUTIVE OFFICER OF NEOVASC INC.

Jan 22 2018

BRIEF-Capital World Investors Reports A 13.8 Percent Passive Stake In Neovasc Inc

* CAPITAL WORLD INVESTORS REPORTS A 13.8 PERCENT PASSIVE STAKE IN NEOVASC INC AS OF NOVEMBER 30, 2017 - SEC FILING Source text : [http://bit.ly/2kZxgLY] Further company coverage:

Dec 11 2017

BRIEF-Neovasc announces qtrly loss per share $0.06

* Neovasc Inc - ‍Revenues decreased 55% to $1.4 million for three months ended September 30, 2017, compared to revenues of $3.0 million ​

Nov 14 2017

BRIEF-Neovasc announces 65 million dollars offering of common shares and warrants

* NEOVASC ANNOUNCES US$65 MILLION UNDERWRITTEN OFFERING OF UNITS CONSISTING OF COMMON SHARES AND WARRANTS TO PURCHASE COMMON SHARES AND CONCURRENT PRIVATE PLACEMENT OF NOTES AND WARRANTS

Nov 10 2017

BRIEF-Neovasc receives FDA approval to initiate pivotal reducer trial

* Neovasc receives FDA approval to initiate pivotal reducer trial

Nov 06 2017

BRIEF-Neovasc provides litigation update

* Says Court Of Appeals affirmed judgment of U.S. District Court for District of Massachusetts in case of Cardiaq Valve Tech versus co

Nov 03 2017

BRIEF-Neovasc provides Tiara clinical update

* Neovasc Inc - ‍all cause, 30-day mortality in 33 patients who have reached 30 days post implant with Tiara is 12.1% (4/33) in Tiara trial​ Source text for Eikon: Further company coverage:

Sep 12 2017

Neovasc loses appeal of $112 million heart valve trade secrets award

A federal appeals court on Friday upheld an almost $112 million win for Edwards Lifesciences Corp, which accused rival medical device company Neovasc Inc of misappropriating its heart valve replacement technology.

Sep 01 2017

Earnings vs. Estimates